Merestinib

Generic Name: Merestinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₂₂F_₂N_₆O_₃

CAS Number: 1206799-15-6

Unique Ingredient Identifier: 5OGS5K699E

Background: Merestinib has been used in trials studying the treatment of Cancer, Solid Tumor, Advanced cancer, ColoRectal Cancer, and Metastatic Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Merestinib on Bone Metastases in Subjects With Breast Cancer

Phase 1

Terminated

Conditions: Bone Metastases
Breast Cancer

Interventions: Drug: Merestinib

First Posted Date: 2017-09-25

Last Posted Date: 2021-01-08

Lead Sponsor: University of Utah

Target Recruit Count: 2

Registration Number: NCT03292536

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Adult Acute Myeloid Leukemia
Relapsed Adult Acute Myeloid Leukemia

Interventions: Drug: Merestinib
Drug: LY2874455

First Posted Date: 2017-04-24

Last Posted Date: 2020-06-30

Lead Sponsor: Jacqueline Garcia, MD

Target Recruit Count: 16

Registration Number: NCT03125239

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Solid Tumor
Cholangiocarcinoma
Gall Bladder Carcinoma
Advanced Cancer
Metastatic Cancer
Biliary Tract Carcinoma
Non-Hodgkin's Lymphoma

Interventions: Drug: Merestinib
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2017-01-23

Last Posted Date: 2020-05-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 19

Registration Number: NCT03027284

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Solid Tumor

Interventions: Drug: Merestinib

First Posted Date: 2016-09-30

Last Posted Date: 2024-04-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT02920996

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Phase 1

Active, not recruiting

Conditions: Cutaneous Melanoma
Pancreatic Cancer
Solid Tumor
Microsatellite Instability-High (MSI-H) Solid Tumors
Breast Cancer (HR+HER2-)

Interventions: Drug: LY3300054
Drug: Ramucirumab
Drug: LY3321367
Drug: Abemaciclib
Drug: Merestinib

First Posted Date: 2016-06-06

Last Posted Date: 2024-05-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 215

Registration Number: NCT02791334

Locations: 🇪🇸
Hospital Madrid Norte Sanchinarro, Madrid, Spain
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 11 locations

A Study of Merestinib (LY2801653) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Merestinib

First Posted Date: 2016-05-20

Last Posted Date: 2016-08-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT02779738

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Phase 1

Completed

Conditions: Advanced Cancer
Colorectal Cancer
Mantle Cell Lymphoma

Interventions: Drug: Ramucirumab
Drug: Merestinib
Drug: Abemaciclib

First Posted Date: 2016-04-20

Last Posted Date: 2019-03-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 23

Registration Number: NCT02745769

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Biliary Tract Cancer
Metastatic Cancer
Advanced Cancer

Interventions: Drug: Cisplatin
Drug: Ramucirumab
Drug: Merestinib
Drug: Placebo IV
Drug: Placebo Oral
Drug: Gemcitabine

First Posted Date: 2016-03-17

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 309

Registration Number: NCT02711553

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 76 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy